Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The "BETTER" Study

Next Previous
X
Search
Trial Profile

TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The "BETTER" Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISTH 0036 (Primary)
  • Indications Age-related macular degeneration; Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms BETTER
  • Sponsors Isarna Therapeutics

    • Most Recent Events

    • 02 May 2024 According to an Isarna Therapeutics media release, updated data from this study has been presented at at the OIS Retina Innovation Summit on May 4th and the Association for Research in Vision and Ophthalmology (ARVO) Meeting on May 7th, 2024, in Seattle, WA.
    • 25 Apr 2024 This trial has been completed in Austria, according to European Clinical Trials Database record.
    • 31 Aug 2022 According to an Isarna Therapeutics media release, full enrollment of patients in this study is expected in the first quarter of 2023 and final data readout expected by the end of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top